Defining meaningful change in Alzheimer's disease trials: the donepezil experience (Q33711100)

28 July 2017

1 reference

title

Defining meaningful change in Alzheimer's disease trials: the donepezil experience (English)

1 reference

28 July 2017

0 references

B M McLendon

1

1 reference

28 July 2017

P M Doraiswamy

series ordinal

2

1 reference

28 July 2017

publication date

1 January 1999

1 reference

Journal of Geriatric Psychiatry and Neurology

28 July 2017

published in

1 reference

28 July 2017

volume

12

1 reference

28 July 2017

issue

1

1 reference

28 July 2017

page(s)

39-48

1 reference

Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

An economic evaluation of donepezil in the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

Clinical-neuropathological correlations in Alzheimer's disease and related dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

Overview of clinical trials of hydergine in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

A new clinical scale for the staging of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

The Global Deterioration Scale for assessment of primary degenerative dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879901200108

10.1177/089198879901200108

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference